GRAPPA Symposium

Date: Monday 8 April 2019
Time: 0830-1230
Location: Room P7, BCEC

Monday 8 April 2019
Time Topic Speaker
0755-0800 Welcome Peter Nash
0800-0840 What’s new in pathogenesis Pso, PsA Bruce Kirkham
0840-0920 Biomarkers in PsA – fact or fiction Oliver Fitzgerald
0920-1000 Outcome measures in PsA – what should we use? Katy Leung
1000-1030 Morning Tea
1100-1300 Supervised US scanning of the Lower limbs All trainers
1030-1100 Co-morbidities Lai Shan Tam
1100-1150 Latest developments in Therapy Marie Feletar
1150-1225 Panel discussion – Derm vs Rheum collaboration or Difficult cases 11
1225-1230 Wrap up Peter Nash

Panel Discussion
Discuss the roles of:

a. Dermatologists, rheumatologists GPs, nurses and patients in the identification, management and treatment of PsA

b. Soluble biomarkers (e.g. highly sensitive C-reactive protein [hsCRP], osteoprotegerin (OPG), etc.) in identifying psoriasis patients who may develop PsA

c. Various screening tests (e.g. Psoriatic Arthritis Screening and Evaluation [PASE] tool, the Psoriasis Epidemiology Screening Tool [PEST], the Toronto Psoriatic Arthritis Screen [ToPAS] and the Early ARthritis for Psoriatic patients [EARP]) to confirm diagnosis

d. Traditional and new biologic agents (e.g. nonsteroidal anti-inflammatory drugs [NSAIDs], steroid and synthetic disease-modifying antirheumatic drugs [DMARDs], proinflammatory cytokine tumor necrosis factor [TNF]) in the treatment of PsA